G. Antonelli, F. Bagnato, C. Pozzilli, E. Simeoni, S. Bastianelli et al., Development of Neutralizing Antibodies in Patients with Relapsing-Remitting Multiple Sclerosis Treated with IFN-??1a, Journal of Interferon & Cytokine Research, vol.18, issue.5, p.345, 1998.
DOI : 10.1089/jir.1998.18.345

C. Boz, J. Oger, E. Gibbs, and S. E. Grossberg, Reduced effectiveness of long-term interferon-?? treatment on relapses in neutralizing antibody-positive multiple sclerosis patients: a Canadian multiple sclerosis clinic-based study, Multiple Sclerosis Journal, vol.48, issue.1, p.1127, 2007.
DOI : 10.1191/1352458504ms1004oa

M. Clanet, E. W. Radue, L. Kappos, H. P. Hartung, R. Hohlfeld et al., A randomized, double-blind, dose-comparison study of weekly interferon ??-1a in relapsing MS, European IFNbeta-1a (Avonex) Dose-Comparison Study Investigators, p.1507, 2002.
DOI : 10.1212/01.WNL.0000032256.35561.D6

J. A. Cohen, G. R. Cutter, J. S. Fischer, A. D. Goodman, F. R. Heidenreich et al., Benefit of interferon ??-1a on MSFC progression in secondary progressive MS, IMPACT Investigators, p.679, 2002.
DOI : 10.1212/WNL.59.5.679

A. Compston and A. Coles, Multiple sclerosis, Lancet, vol.359, 1221.
URL : https://hal.archives-ouvertes.fr/hal-00996686

J. G. Files, J. L. Gray, L. T. Do, W. P. Foley, J. D. Gabe et al., A Novel Sensitive and Selective Bioassay for Human Type I Interferons, Journal of Interferon & Cytokine Research, vol.18, issue.12, 1019.
DOI : 10.1089/jir.1998.18.1019

S. E. Grossberg, Y. Kawade, M. Kohase, and J. P. Klein, The Neutralization of Interferons by Antibody. II. Neutralizing Antibody Unitage and Its Relationship to Bioassay Sensitivity: The Tenfold Reduction Unit, Journal of Interferon & Cytokine Research, vol.21, issue.9, p.743, 2001.
DOI : 10.1089/107999001753124471

L. D. Jacobs, D. L. Cookfair, R. A. Rudick, R. M. Herndon, J. R. Richert et al., Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis, Annals of Neurology, vol.43, issue.3, p.285, 1996.
DOI : 10.1002/ana.410390304

L. D. Jacobs, R. W. Beck, J. H. Simon, R. P. Kinkel, C. M. Brownscheidle et al., Intramuscular Interferon Beta-1A Therapy Initiated during a First Demyelinating Event in Multiple Sclerosis, New England Journal of Medicine, vol.343, issue.13, p.898, 2000.
DOI : 10.1056/NEJM200009283431301

R. Lam, R. Farrell, T. Aziz, E. Gibbs, G. Giovannoni et al., Validating parameters of a luciferase reporter gene assay to measure neutralizingantibodies to IFN beta in multiple sclerosis patients, J. Immunol. Methods, vol.336, issue.113, 2008.

P. Jr, E. Files, J. G. Gabe, J. D. Do, L. T. Foley et al., A novel bioassay for the determination of neutralizing antibodies to IFN-beta1b, J. Interferon Cytokine Res, vol.18, 1025.

H. Schellekens, Bioequivalence and the immunogenicity of biopharmaceuticals, Nature Reviews Drug Discovery, vol.1, issue.6, p.457, 2002.
DOI : 10.1038/nrd818

G. Uzé, D. Marco, S. Mouchel-vielh, E. Monneron, D. Bandu et al., Domains of Interaction between Alpha Interferon and its Receptor Components, Journal of Molecular Biology, vol.243, issue.2, p.245, 1994.
DOI : 10.1006/jmbi.1994.1651

. Fig, The scatter plot for logarithm of NAb titers measured by luciferase (UBC) vs. CPE (Iran) Titers are expressed in log10. Spearman coefficient r=0